

## What is the purpose of the MIRNA study?

Fatty liver disease and NASH are 'silent' diseases, which means that many people will be completely unaware that they are at risk of liver damage.<sup>2</sup> If left untreated, NASH can lead to cirrhosis (scarring of the liver), liver cancer, the need for liver transplantation and even death.<sup>1</sup> Currently there is no medical treatment available for NASH with fibrosis.

The MIRNA study aims to identify people with NASH with liver fibrosis and investigate the potential benefits of two different study drugs to treat this disease.

While there is no guarantee that you will receive any benefit from the study drugs you receive, you may be helping to advance medical knowledge of NASH with fibrosis and will receive support from the study team throughout the study.

## Find out more

To learn more about the MIRNA study, please contact us:

Principal Investigator: Dr. Mindie Nguyen  
Div. of Gastroenterology and Hepatology  
Stanford University Medical Center

Study Coordinator: Akiko Mizuta  
Email: [amizuta@stanford.edu](mailto:amizuta@stanford.edu)  
Phone: (408)431-7567

For participant's rights questions, contact 1-866-680-2906.

Contacting us doesn't mean you have to join the study and we would like to reassure you that you can change your mind at any time if you feel the study isn't right for you.

You can also find out more about the MIRNA study by visiting

[www.MIRNAstudy.com](http://www.MIRNAstudy.com)


### References:

1. Younossi ZM. J Hepatol 2019; 70: 531-544.
2. Chopra S. Patient education: Nonalcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) (Beyond the Basics). UpToDate.com. Available at: <https://www.uptodate.com/contents/nonalcoholic-fatty-liver-disease-nafl-d-including-non-alcoholic-steatohepatitis-nash-beyond-the-basics> Accessed March 2020.
3. The Truth About Clinical Trials. Healthline.com. Available at: <https://www.healthline.com/health/truth-about-clinical-trials#1> Accessed March 2020.



**1 in 4 people in the world have fatty liver<sup>1</sup>**  
Even with no symptoms, this could be you.

Having a fatty liver can lead to a more advanced form of liver disease called nonalcoholic steatohepatitis (NASH), where there is inflammation and damage (scarring)<sup>2</sup>



## The MIRNA study

The MIRNA study will investigate the potential benefits of two different study drugs for the treatment of NASH with liver fibrosis.

### Could this study be an option for me?

The MIRNA study may be an option for you if you are aged 18-75 and have at least two of the following conditions:

- Overweight or obesity
- Type 2 diabetes
- High cholesterol
- High triglycerides (a type of fat in the blood)
- High blood pressure

There are other requirements for participation in the study. The study doctor will be able to explain these to you.

## What is involved?

During the screening phase of the study, a number of healthcare assessments and physical examinations will be carried out, including a FibroScan® to assess liver fat/stiffness and a liver biopsy to confirm a diagnosis of NASH with fibrosis. Some participants may also have an MRI.

From baseline to the end of the study, you will be asked to take 3 tablets twice a day for 50 weeks.

So that we can monitor how you are responding to the treatment, you will need to make regular visits to the clinic for health assessments such as medical questionnaires, alcohol intake questionnaires, physical examinations, blood and urine samples, FibroScan® (and MRIs if required) plus have a second liver biopsy at the end of the treatment phase.

## Why participate?

Clinical research brings people together to help compare investigational medicines with current standard of care treatments.

Some of the reasons study participants gave when asked why they decided to join a study were:<sup>3</sup>

- To help scientific research
- To have access to different treatments
- To receive additional care

The results seen in the MIRNA study may help to guide future research for treatments in NASH with fibrosis.

